BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 21411598)

  • 21. Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials.
    Bhutta ZA; Capeding MR; Bavdekar A; Marchetti E; Ariff S; Soofi SB; Anemona A; Habib MA; Alberto E; Juvekar S; Khan RM; Marhaba R; Ali N; Malubay N; Kawade A; Saul A; Martin LB; Podda A
    Lancet Infect Dis; 2014 Feb; 14(2):119-29. PubMed ID: 24290843
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A combined Haemophilus influenzae type B Neisseria meningitidis serogroup C tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when coadministered with diphtheria, tetanus, acellular pertussis hepatitis B-inactivated poliovirus at 3, 5 and 11 months of age: results of an open, randomized, controlled study.
    Vesikari T; Forstén A; Desole MG; Ferrera G; Caubet M; Mesaros N; Boutriau D
    Pediatr Infect Dis J; 2013 May; 32(5):521-9. PubMed ID: 23190785
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Physical and chemical characterization and immunologic properties of Salmonella enterica serovar typhi capsular polysaccharide-diphtheria toxoid conjugates.
    Cui C; Carbis R; An SJ; Jang H; Czerkinsky C; Szu SC; Clemens JD
    Clin Vaccine Immunol; 2010 Jan; 17(1):73-9. PubMed ID: 19889941
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Does concomitant injection of a combined diphtheria-tetanus-acellular pertussis - hepatitis B virus - inactivated polio virus vaccine influence the reactogenicity and immunogenicity of commercial Haemophilus influenzae type b conjugate vaccines?
    Usonis V; Bakasenas V
    Eur J Pediatr; 1999 May; 158(5):398-402. PubMed ID: 10333123
    [TBL] [Abstract][Full Text] [Related]  

  • 25. First characterization of immunogenic conjugates of Vi negative Salmonella Typhi O-specific polysaccharides with rEPA protein for vaccine development.
    Salman M; St Michael F; Ali A; Jabbar A; Cairns C; Hayes AC; Rahman M; Iqbal M; Haque A; Cox AD
    J Immunol Methods; 2017 Nov; 450():27-33. PubMed ID: 28735760
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 13-valent pneumococcal conjugate vaccine given with meningococcal C-tetanus toxoid conjugate and other routine pediatric vaccinations: immunogenicity and safety.
    Martinón-Torres F; Gimenez-Sanchez F; Gurtman A; Bernaola E; Diez-Domingo J; Carmona A; Sidhu M; Sarkozy DA; Gruber WC; Emini EA; Scott DA;
    Pediatr Infect Dis J; 2012 Apr; 31(4):392-9. PubMed ID: 22301472
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomised trial of the effect of co-administration with acellular pertussis DTP vaccine on immunogenicity of Haemophilus influenzae type b conjugate vaccine.
    Eskola J; Olander RM; Hovi T; Litmanen L; Peltola S; Käyhty H
    Lancet; 1996 Dec 21-28; 348(9043):1688-92. PubMed ID: 8973430
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibody responses and symptoms after DTP and either tetanus or diphtheria Haemophilus influenzae type B conjugate vaccines given for primary immunisation by separate or mixed injection.
    Begg NT; Miller E; Fairley CK; Chapel HM; Griffiths H; Waight PA; Ashworth LA
    Vaccine; 1995 Nov; 13(16):1547-50. PubMed ID: 8578840
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity and reactogenicity of a Haemophilus influenzae type b tetanus conjugate vaccine when administered separately or mixed with concomitant diphtheria-tetanus-toxoid and acellular pertussis vaccine for primary and for booster immunizations.
    Schmitt HJ; Zepp F; Müschenborn S; Sümenicht G; Schuind A; Beutel K; Knuf M; Bock HL; Bogaerts H; Clemens R
    Eur J Pediatr; 1998 Mar; 157(3):208-14. PubMed ID: 9537487
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C (HibMenC) or serogroup C and Y-tetanus toxoid conjugate (and HibMenCY) vaccines are well-tolerated and immunogenic when administered according to the 2,3,4 months schedule with a fourth dose at 12-18 months of age.
    Habermehl P; Leroux-Roels G; Sänger R; Mächler G; Boutriau D
    Hum Vaccin; 2010 Aug; 6(8):640-51. PubMed ID: 20697200
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of neonatal immunization with diphtheria and tetanus toxoids on antibody responses to Haemophilus influenzae type b conjugate vaccines.
    Lieberman JM; Greenberg DP; Wong VK; Partridge S; Chang SJ; Chiu CY; Ward JI
    J Pediatr; 1995 Feb; 126(2):198-205. PubMed ID: 7844665
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Maternal immunization with Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine in The Gambia.
    Mulholland K; Suara RO; Siber G; Roberton D; Jaffar S; N'Jie J; Baden L; Thompson C; Anwaruddin R; Dinan L; Glezen WP; Francis N; Fritzell B; Greenwood BM
    JAMA; 1996 Apr; 275(15):1182-8. PubMed ID: 8609686
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and immunogenocity of a novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C-tetanus-toxoid conjugate vaccine in healthy Chinese children aged 6 months to 5 years old.
    Hu JL; Tao H; Li JX; Dai WM; Song B; Sun JF; Liu P; Tang J; Liu WY; Wang SY; Zhu FC
    Hum Vaccin Immunother; 2015; 11(5):1120-8. PubMed ID: 25833163
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Six-month follow up of a randomized clinical trial-phase I study in Indonesian adults and children: Safety and immunogenicity of Salmonella typhi polysaccharide-diphtheria toxoid (Vi-DT) conjugate vaccine.
    Medise BE; Soedjatmiko S; Rengganis I; Gunardi H; Sekartini R; Koesno S; Satari HI; Hadinegoro SR; Yang JS; Excler JL; Sahastrabuddhe S; Puspita M; Sari RM; Bachtiar NS
    PLoS One; 2019; 14(2):e0211784. PubMed ID: 30759132
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Associated or combined vaccination of Brazilian infants with a conjugate Haemophilus influenzae type b (Hib) vaccine, a diphtheria-tetanus-whole-cell pertussis vaccine and IPV or OPV elicits protective levels of antibodies against Hib.
    Araújo OO; Forleo-Neto E; Vespa GN; Puccini RF; Weckx LW; Carvalho ES; Farhat CK
    Vaccine; 2000 Sep; 19(2-3):367-75. PubMed ID: 10930692
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and immunogenicity of a Vi-DT typhoid conjugate vaccine: Phase I trial in Healthy Filipino adults and children.
    Capeding MR; Teshome S; Saluja T; Syed KA; Kim DR; Park JY; Yang JS; Kim YH; Park J; Jo SK; Chon Y; Kothari S; Yang SY; Ham DS; Ryu JH; Hwang HS; Mun JH; Lynch JA; Kim JH; Kim H; Excler JL; Sahastrabuddhe S
    Vaccine; 2018 Jun; 36(26):3794-3801. PubMed ID: 29776750
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity and safety of two different Haemophilus influenzae type b conjugate vaccines in Korean infants.
    Kim KH; Lee H; Chung EH; Kang JH; Kim JH; Kim JS; Lee HJ; Oh SH; Park EA; Park SE
    J Korean Med Sci; 2008 Dec; 23(6):929-36. PubMed ID: 19119431
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of carrier protein priming on antibody responses to Haemophilus influenzae type b conjugate vaccines in infants.
    Granoff DM; Holmes SJ; Belshe RB; Osterholm MT; McHugh JE; Anderson EL
    JAMA; 1994 Oct; 272(14):1116-21. PubMed ID: 7933324
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity and safety of Haemophilus influenzae type b-tetanus protein conjugate vaccine alone or mixed with diphtheria-tetanus-pertussis vaccine in infants.
    Kaplan SL; Lauer BA; Ward MA; Wiedermann BL; Boyer KM; Dukes CM; Schaffer DM; Paisley J; Mendelson R; Pedreira F
    J Pediatr; 1994 Feb; 124(2):323-7. PubMed ID: 8301447
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Co-administration of a novel Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine does not interfere with the immune response to antigens contained in infant vaccines routinely used in the United States.
    Marshall GS; Marchant CD; Blatter M; Friedland LR; Aris E; Miller JM
    Hum Vaccin; 2011 Feb; 7(2):258-64. PubMed ID: 21307655
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.